Friedreich's Ataxia Research Alliance (FARA) Joins with MDA and Seek A Miracle in Fighting Friedreich’s Ataxia
Washington, D.C. — The Friedreich's Ataxia Research Alliance (FARA) has awarded a $300,000 grant to Edison Pharmaceuticals in the first step of an ongoing collaboration with the Muscular Dystrophy Association (MDA), and Seek A Miracle (SAM), intended to move promising compounds for the treatment of neuromuscular diseases from the lab to the clinic.
The initial FARA grant is to fund the pre-clinical toxicology and pharmacology on clinical candidates developed by Guy Miller, MD, PhD and the team of Edison Pharmaceuticals of San Jose, California.
"FARA is very excited to work with MDA and SAM on this project," said Ron Bartek, FARA’s president. "We believe these compounds show real promise in addressing the respiratory chain defect present in Friedreich’s ataxia patients. Our hope is that clinical candidates such as Edison’s EPI-A0001 will form the basis of a first-line treatment in arresting the progression of FA."
Read more: Friedreich's Ataxia Research Alliance (FARA) Joins with MDA and Seek A Miracle in Fighting...